Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 16/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.35 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2702034 | 0.82 | CNR2 (0.39) | APPTHRBKMT2AALDH1A1 | |
| SCHEMBL1591485 | 0.79 | SLC13A5 (0.40) | APPTHRBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL18600902 | 0.79 | APP (0.54) | APPKCNJ5KCNJ3LMNASMN1; SMN2 | |
| SCHEMBL2374306 | 0.79 | APP (0.54) | APP | |
| SCHEMBL18371936 | 0.76 | APP (0.35) | APPPTGS2KCNJ5KCNJ3THRB | |
| SCHEMBL1845695 | 0.75 | SLC13A5 (0.37) | LMNASMN1; SMN2 | |
| SCHEMBL18600965 | 0.75 | APP (0.50) | APPPTGS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL14823453 | 0.74 | PTGS2 (0.38) | APPPTGS2THRBKMT2AALDH1A1 | |
| SCHEMBL12862764 | 0.73 | ALDH1A1 (0.36) | APPKCNJ5KCNJ3KMT2AALDH1A1 | |
| SCHEMBL7180070 | 0.73 | KDM4E (0.48) | THRBKMT2AALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2018-07-26 | — | — | US | disclosed |
| US-9896441-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170183331-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183331-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | APP 2173/4885PTGS2 1029/4885KCNJ5 1365/4885 |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | APP 2173/4885PTGS2 1029/4885KCNJ5 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.